Abstract

Neuraminidase (NA) of influenza is a key target for antiviral inhibitors, and the 150-cavity in group-1 NA provides new insight in treating this disease. However, NA of 2009 pandemic influenza (09N1) was found lacking this cavity in a crystal structure. To address the issue of flexibility of the 150-loop, Hamiltonian replica exchange molecular dynamics simulations were performed on different groups of NAs. Free energy landscape calculated based on the volume of 150-cavity indicates that 09N1 prefers open forms of 150-loop. The turn A (residues 147–150) of the 150-loop is discovered as the most dynamical motif which induces the inter-conversion of this loop among different conformations. In the turn A, the backbone dynamic of residue 149 is highly related with the shape of 150-loop, thus can function as a marker for the conformation of 150-loop. As a contrast, the closed conformation of 150-loop is more energetically favorable in N2, one of group-2 NAs. The D147-H150 salt bridge is found having no correlation with the conformation of 150-loop. Instead the intimate salt bridge interaction between the 150 and 430 loops in N2 variant contributes the stabilizing factor for the closed form of 150-loop. The clustering analysis elaborates the structural plasticity of the loop. This enhanced sampling simulation provides more information in further structural-based drug discovery on influenza virus.

Highlights

  • Influenza virus causes a great threat to people when it emerges as pandemic through reassortment during coinfection of different host species [1]

  • Because influenza virus infection cannot be completely prevented by vaccination, antiviral drugs are still necessary for the therapeutic treatment of influenza [6]

  • In N2 system, the Root mean squared deviation (RMSD) values with respect to the putative open conformation maintained higher than 0.75 nm indicating the sampled conformations are quite different from the putative open conformation

Read more

Summary

Introduction

Influenza virus causes a great threat to people when it emerges as pandemic through reassortment during coinfection of different host species [1]. In order to prevent and control the influenza virus infections, two strategies could apply: vaccines and antiviral drugs. It takes three to six months to create a vaccine in treating a newly emerged virus strain. During this period, the novel strain can spread globally, infect human and cause great damage to the economy [5]. The novel strain can spread globally, infect human and cause great damage to the economy [5] In this lag phase, taking antiviral drugs is the only available approach in controlling and stopping influenza infections. Because influenza virus infection cannot be completely prevented by vaccination, antiviral drugs are still necessary for the therapeutic treatment of influenza [6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call